FRM
ADPT icon

Fox Run Management’s Adaptive Biotechnologies ADPT Stock Holding History

Fox Run Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,983
Closed -$598K – 873
2025
Q3 		$598K Buy
39,983
+19,788
+98% +$241K 0.09% 418
2025
Q2 		$235K Sell
20,195
-1,370
-6% -$12.4K 0.04% 712
2025
Q1 		$160K Buy
21,565
+1,631
+8% +$12.5K 0.02% 822
2024
Q4 		$120K Buy
+19,934
New +$110K 0.02% 795
2023
Q3 		– Sell
-21,724
Closed -$146K – 674
2023
Q2 		$146K Buy
21,724
+1,375
+7% +$10.2K 0.04% 616
2023
Q1 		$180K Buy
20,349
+1,124
+6% +$9.91K 0.06% 552
2022
Q4 		$147K Buy
+19,225
New +$150K 0.06% 528
2022
Q2 		– Sell
-14,491
Closed -$201K – 498
2022
Q1 		$201K Buy
+14,491
New +$228K 0.11% 416
2021
Q4 		– Sell
-8,912
Closed -$303K – 449
2021
Q3 		$303K Buy
+8,912
New +$322K 0.19% 226

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fox Run Management's ADPT Position: Q4 2025 in Review

Fox Run Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 39,983 shares — an estimated $598K sold.

Fox Run Management first reported a position in ADPT in Q3 2021 and held it in 9 quarters. The position peaked at $598K in Q3 2025. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • Fox Run Management reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 39,983 Adaptive Biotechnologies shares in Q4 2025, an estimated $598K.
  • Fox Run Management first reported a position in Adaptive Biotechnologies in Q3 2021 and held it in 9 quarters.
  • Fox Run Management's Adaptive Biotechnologies position peaked at $598K in Q3 2025.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.